Implications of the ADVANCE study for clinical practice

Journal of Hypertension

Volumn 26, Issue SUPPL. 3, 2008, Pages

  Zannad, Faiez ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

ADVANCE; Cardiovascular; Hypertension; Perindopril indapamide; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; INDAPAMIDE; PERINDOPRIL;

DRUG COMBINATION; HUMAN; HYPERTENSION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; INDAPAMIDE; PERINDOPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 65549094093     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/01.hjh.0000334075.42823.3e     Document Type: Article

References (13)

1. Parving HH. Diabetic hypertensive patients. Is this a group in need of particular care and attention? Diabetes Care 1999;22(Suppl. 2):B76-B79.
2. Schutta MH. Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J Cardiometab Syndr 2007;2:124-130.
3. Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 2007;67:997-1026. (Pubitemid 46744476)
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
5. HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-259.
6. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, et al., ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide onmacrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840. (Pubitemid 47362321)
7. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187. (Pubitemid 46924065)
8. ADVANCE Collaborative Group. ADVANCE - Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet Med 2005;22:882-888.
9. ADVANCE Management Committee. Study rationale and design of ADVANCE: Action in Diabetes and Vascular disease - preterax and diamicron MR Controlled Evaluation. Diabetologia 2001;44:1118-1120.
10. Chalmers J, Perkovic V, Joshi R, Patel A. ADVANCE: breaking new ground in type 2 diabetes. J Hypertens 2006;24(Suppl. 5):S22-S28. (Pubitemid 44299478)
11. Lindholm LH, Ibsen H, Dalhof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-1010. (Pubitemid 34286537)
12. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2diabetesand overt nephropathy. Ann Intern Med 2003;138:542-549.
13. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.